Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial
(2024)
Journal Article
Muir, K. W., Ford, G. A., Ford, I., Wardlaw, J. M., McConnachie, A., Greenlaw, N., Mair, G., Sprigg, N., Price, C. I., MacLeod, M. J., Dima, S., Venter, M., Zhang, L., O'Brien, E., Sanyal, R., Reid, J., Sztriha, L. K., Haider, S., Whiteley, W. N., Kennedy, J., …Douglass, C. (2024). Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurology, 23(11), 1087-1096. https://doi.org/10.1016/S1474-4422%2824%2900377-6
Background: Tenecteplase has potential benefits over alteplase, the standard agent for intravenous thrombolysis in acute ischaemic stroke, because it is administered as a single bolus and might have superior efficacy. The ATTEST-2 trial investigated...
Read More about Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.